Pernix治療控股 PTXTQ 深 滬
等待開盤 07-18 09:30:00 美东时间
0.00
0.000
NaN.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 0.00
- 總市值 0
- 52周最高 0.00
- 市盈率 靜 --
- 換手率 NaN.00%
- 52周最低 0.00
- 委 比 0.00%
- 總股本 --
- 歷史最高 0.00
- 量 比 0
- 振 幅 NaN.00%
- 歷史最低 0.00
- 每 手 1
- 風險率
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Plus Therapeutics Announces FDA Agreement to Initiate ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases
Houston-based Plus Therapeutics has initiated the ReSPECT-LM dose optimization trial for REYOBIQ, targeting leptomeningeal metastases (LM). Building on Phase 1 results, the trial aims to determine optimal dosing regimens for maximum safety and efficacy, supported by a $17.6M CPRIT grant. Previously, the single-dose trial demonstrated a 76% clinical benefit rate and no dose-limiting toxicities in early cohorts. The ReSPECT-LM trial will enroll up ...
06-30 11:30
Palvella Therapeutics Added to Russell 3000® and Russell 2000® Indexes
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on treating serious, rare genetic skin diseases without FDA-approved therapies, has been added to the Russell 3000® and Russell 2000® indexes effective June 30, 2025. Membership in these indexes reflects the company's market capitalization and is part of the annual reconstitution process. Palvella is developing a pipeline of product candidates, including its lead QTOR...
06-30 11:30
Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Phathom Pharmaceuticals has granted inducement awards to Anne Marie Cook upon her appointment as Chief Legal Officer and Corporate Secretary. The awards include non-qualified stock options for 210,000 shares, vesting over four years, and performance-based stock units tied to financial goals over three years, under the 2025 Inducement Plan. Phathom specializes in novel treatments for gastrointestinal diseases and markets vonoprazan-based products,...
06-23 20:15
